Common use of Indemnification Provisions Clause in Contracts

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus Biopharmaceuticals, Inc. (the “Company”) pursuant to a letter agreement dated August 25, 2016 between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group Group, LLC (“Maxim”) by Provectus BiopharmaceuticalsPro-Pharmaceuticals, Inc. (the “Company”) pursuant to a letter placement agreement dated August 25February 12, 2016 2008, between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus Biopharmaceuticals, Inc. Prima BioMed Ltd (the “Company”) pursuant to a letter agreement dated August 25March 31, 2016 2017, between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus BiopharmaceuticalsSELLAS Life Sciences Group, Inc. (the “Company”) pursuant to a letter agreement dated August 25December 11, 2016 2020, between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus Biopharmaceuticals, Inc. Adamis Pharmaceuticals Corporation. (the “Company”) pursuant to a letter agreement dated August 25July 29, 2016 between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus Biopharmaceuticals, Inc. Genetic Technologies Limited (the “Company”) pursuant to a letter agreement dated August 25September 9, 2016 2016, between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus Biopharmaceuticals, Pluristem Therapeutics Inc. (the “Company”) pursuant to a letter agreement dated August June 25, 2016 2015, between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus BiopharmaceuticalsInterpace Diagnostics Group, Inc. (the “Company”) pursuant to a letter agreement dated August 25December 19, 2016 between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus BiopharmaceuticalsApplied DNA Sciences, Inc. (the “Company”) pursuant to a letter agreement dated August 25November 17, 2016 2015, between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus Biopharmaceuticals, Inc. Genetic Technologies Limited (the “Company”) pursuant to a letter agreement dated August 25March 6, 2016 2015, between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus BiopharmaceuticalsInterpace Diagnostics Group, Inc. (the “Company”) pursuant to a letter agreement dated August 25January 20, 2016 2017 between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows:

Indemnification Provisions. In connection with the engagement of Maxim Group LLC (“Maxim”) by Provectus BiopharmaceuticalsStellar Biotechnologies, Inc. (the “Company”) pursuant to a letter agreement dated August 25June 27, 2016 2016, between the Company and Maxim, as it may be amended from time to time in writing (the “Agreement”), the Company hereby agrees as follows: